Response of Patients with Transfusion-Dependent ß-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers.

Blood

Mark C. Walters, David H.K. Chui, John J Farrell, Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, John B. Porter, Martin G. Sauer, Isabelle Thuret, Suradej Hongeng, Andreas E. Kulozik, Adrian J. Thrasher, Evangelia Yannaki, Julia Yang, Dustin Whitney, Alexandria Petrusich, Richard A. Colvin, Alexis A. Thompson. Response of Patients with Transfusion-Dependent ß-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers. Blood. 2020 Nov 5; 136(Supplement 1):1-3.

2020

https://researcherprofiles.org/profile/425025743

Northern California Comprehensive Thalassemia Center

Search form

You are here

Response of Patients with Transfusion-Dependent ß-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers.